The Wheel Strategy on MRK (Merck): Full Setup, Sizing, and Real-World Numbers
What's in this guide
1. Why MRK as a wheel candidate 2. The risks — patent cliffs + drug approvals 3. Strike selection on MRK 4. Position sizing 5. A worked example — full cycle 6. Special considerations (dividend, earnings, FDA) 7. The mistakes wheelers make on MRK 8. Next stepsMRK (Merck & Co.) is one of the largest US pharmaceutical companies, best known for Keytruda (oncology) which is projected to become the best-selling drug in history before patent expiry in 2028. For wheelers, MRK offers a solid 3-3.5% dividend, moderate IV, and mega-pharma stability — but the Keytruda patent cliff is a specific long-term risk to plan around.
This guide walks through the complete wheel setup on MRK — how to size, which strikes to sell, and what to expect through a real cycle.
1. Why MRK as a wheel candidate
- Solid dividend (~3-3.5% yield) — Dividend Aristocrat status
- Moderate IV (~20-30%) — decent premium with reasonable stability
- Deep options liquidity — tight spreads
- Keytruda dominance — best-selling drug through 2028
- Strong pipeline — Winrevair, sotatercept, other oncology assets
- Non-cyclical demand — pharma revenue is recession-resistant
2. The risks — patent cliffs + drug approvals
MRK has specific risks wheelers should know:
- Keytruda patent cliff (2028): $27B in annual revenue faces generic competition — this is the single largest overhang
- FDA approval risk: pipeline drug rejections can move shares 5-15%
- Drug pricing regulation: Medicare negotiation under Inflation Reduction Act pressures pricing
- Litigation: pharma routinely faces product liability lawsuits
3. Strike selection on MRK
Standard framework:
| Situation | Suggested delta | DTE |
|---|---|---|
| Normal conditions (IV rank 30-60) | 0.20-0.25 delta | 35-45 DTE |
| Elevated IV (drug news, IV rank 60+) | 0.15-0.20 delta | 35-45 DTE |
| Low IV (IV rank <30) | 0.20-0.25 delta | 30 DTE (shorter) |
| Before major FDA approval decisions | Wait until decision released | Post-news |
4. Position sizing
MRK at $95 requires $9,500 per contract. Sizing rules:
- Max 20% of wheel capital in MRK specifically
- Never let MRK + LLY + PFE + JNJ exceed combined 30% (pharma concentration)
- Keep 30%+ cash cushion — FDA decisions can gap shares overnight
5. A worked example — full cycle
MRK at $95, IV rank 45, no earnings for 40 days, no imminent FDA catalysts. You have $9,500 for this position:
| Day | Action | Result | Cumulative P/L |
|---|---|---|---|
| 0 | Sell 1 MRK $92P, 35 DTE, 0.22 delta | Collect $170 premium | +$170 |
| 24 | Put worth $80 (53% profit). Buy to close. | Free capital. | +$90 net |
| 24 | Sell 1 MRK $93P, 35 DTE, 0.22 delta | Collect $180 premium | +$270 |
| 59 | MRK at $97 at expiration; put expired worthless. | Kept full $180. | +$270 |
$270 on $9,500 in 2 months = ~2.8% for cycle, ~17% annualized on premium alone. Add dividend when assigned (~$0.80/qtr per share = ~3.4% additional annual yield when holding).
6. Special considerations
A. Dividend
MRK pays ~$3.10/year per share (~3.3% yield at $95). Quarterly dividends ~$0.77. Dividend Aristocrat consistency provides steady income. When holding shares, dividend income is approximately $77/quarter per contract.
B. Earnings
MRK reports quarterly. Rarely moves >5% on earnings but occasionally does on Keytruda revenue trajectory or pipeline data. Standard rule: no new positions 7 days before earnings.
C. FDA + drug approval catalysts
FDA approval decisions on major pipeline drugs (Winrevair, sotatercept, next-gen oncology) can move MRK 5-15% intraday. Track FDA calendar (PDUFA dates); reduce size or step aside in the 3-5 days before major decisions. This is unique to pharma — not comparable to normal earnings volatility.
7. The mistakes wheelers make on MRK
Mistake #1: Ignoring the Keytruda 2028 patent cliff
Keytruda is 40%+ of MRK's revenue. Post-2028 generic competition will pressure that revenue base. Not an immediate concern (still 2 years out at 2026), but wheelers holding long-term should watch how MRK's pipeline transitions.
Mistake #2: Overallocating to pharma
MRK + LLY + PFE + JNJ correlate on sector news. Cap combined pharma at 30% of wheel capital.
Mistake #3: Trading through unknown FDA calendars
Wheelers who don't track PDUFA dates get surprised by big overnight moves on approval/rejection news. Add MRK's pipeline catalysts to your trading calendar.
8. Next steps
- Verify MRK fits your account — $9,500 per contract, max 20% of wheel capital
- Use 0.20-0.25 delta, 35-45 DTE puts as the default
- Track FDA calendar for major MRK pipeline decisions
- Diversify beyond pharma — never all-in on MRK + LLY + PFE + JNJ
For real weekly wheel trades I run in my own account, the Omega Membership shares the trade plan. Or grab the free Starter Kit.
Ready to shadow real wheel trades?
The Omega Membership is the weekly trade plan I run in my own account — Sunday market prep, live calls, and the members' Discord.
See the membership → Free Starter KitFrequently asked questions
Is MRK a good stock for the wheel strategy?
Yes with one caveat. Pros: solid ~3-3.5% dividend (Dividend Aristocrat), moderate IV (~20-30%), deep options liquidity, Keytruda dominance through 2028, non-cyclical demand. Main caveat: Keytruda 2028 patent cliff is a specific long-term overhang (Keytruda = 40%+ of revenue). Best for wheelers comfortable with sector-specific risks.
How much capital do I need to wheel MRK?
One contract requires ~$9,500 at $95/share × 100. Practical minimum for responsible sizing (MRK not exceeding 20% of wheel capital) is around $50,000+ total capital.
What delta should I use for MRK puts?
0.20-0.25 delta as the default in normal IV conditions (~20-30%). Drop to 0.15-0.20 delta if IV is elevated (post-drug-news, before FDA decisions). MRK is moderate volatility — less than growth pharma but higher than defensive consumer names.
How does the Keytruda patent cliff affect wheeling MRK?
Not an immediate concern at 2026 (still 2 years away) but real long-term. Keytruda = 40%+ of MRK revenue; post-2028 generic competition will pressure that base. Wheelers can trade MRK normally through 2027 but should watch how the pipeline transitions and be ready to reduce or step aside if concerns intensify closer to 2028.
Does MRK pay a dividend for the wheel?
Yes — ~$3.10/year per share (~3.3% yield at $95), paid quarterly. When holding shares, dividend income is approximately $77/quarter per contract. Dividend Aristocrat status provides steady, growing income.
Should I wheel MRK through FDA approval decisions?
Reduce size or step aside. Major FDA decisions on MRK's pipeline (Winrevair, sotatercept, next-gen oncology) can move shares 5-15% intraday. Track PDUFA dates; no new positions 3-5 days before major decisions. This is unique to pharma and requires more attention than normal earnings.
What are the biggest risks of wheeling MRK?
Four specific ones: (1) Keytruda 2028 patent cliff — 40%+ of revenue faces generic competition, (2) FDA approval risk — pipeline drug rejections can move shares 5-15%, (3) drug pricing regulation under Inflation Reduction Act, (4) product liability litigation (routine for pharma).
MRK vs LLY vs PFE for the wheel — which is better?
All three work for pharma exposure. LLY is more expensive (~$780/share = $78k/contract, higher IV, more growth-oriented). MRK is moderate ($95/share = $9.5k, solid dividend, Keytruda cliff overhang). PFE is cheapest (~$25/share, lowest quality of the three, higher yield). Pick based on account size and risk appetite.
When should I skip wheeling MRK?
Four situations: (1) 3-5 days before major FDA decisions on pipeline drugs, (2) 7 days before earnings, (3) during active political discussion of drug pricing regulation, (4) if you already have significant pharma exposure through LLY/PFE/JNJ (concentration risk).